Literature DB >> 16435160

Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study.

Chris T Derk1, Carol M Artlett, Sergio A Jimenez.   

Abstract

This study aims to characterize the clinical features of a cohort of patients diagnosed with systemic sclerosis (SSc) after the age of 75 and compare them to a group diagnosed at a younger age. We record the review of 769 patients diagnosed with SSc over the past 16 years. Utilizing a nested case-control model, we compare demographics, disease severity, morbidity, and mortality data of all patients diagnosed after the age of 75 to sex- and disease-type-matched, randomly selected group of patients diagnosed with SSc before the age of 60. Twelve patients were diagnosed with SSc after the age of 75, seven with the diffuse, and five with the limited form. It took longer to diagnose SSc in the older patients, and comparison of disease severity revealed a worse pulmonary picture and a more frequent development of malignancy in the older patients as compared with the younger ones. During a mean follow-up of 36.2 months, our cohort of patients did not have worsening in their disease severity, though 6 months after the last follow-up, six patients died. We conclude that a diagnosis of SSc at an older age appears to be a poor prognostic indicator related to both disease severity and comorbidities. A higher clinical suspicion will lead to an earlier diagnosis and a potential decrease in morbidity and mortality.

Entities:  

Mesh:

Year:  2006        PMID: 16435160     DOI: 10.1007/s10067-005-0177-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

Review 1.  Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis.

Authors:  Sergio A Jimenez; Chris T Derk
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

2.  Systemic scleroderma, A clinical study of 727 cases.

Authors:  D L TUFFANELLI; R K WINKELMANN
Journal:  Arch Dermatol       Date:  1961-09

3.  Systemic sclerosis in the elderly.

Authors:  L Czirják; Z Nagy; G Szegedi
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

4.  Progressive systemic sclerosis in the elderly.

Authors:  J A Dalziel; G K Wilcock
Journal:  Postgrad Med J       Date:  1979-03       Impact factor: 2.401

5.  Scleroderma in the elderly, with special reference to the CRST syndrome.

Authors:  H M Hodkinson
Journal:  J Am Geriatr Soc       Date:  1971-03       Impact factor: 5.562

Review 6.  Scleroderma--demographics and survival.

Authors:  A J Silman
Journal:  J Rheumatol Suppl       Date:  1997-05

7.  A disease severity scale for systemic sclerosis: development and testing.

Authors:  T A Medsger; A J Silman; V D Steen; C M Black; A Akesson; P A Bacon; C A Harris; S Jablonska; M I Jayson; S A Jimenez; T Krieg; E C Leroy; P J Maddison; M L Russell; R K Schachter; F A Wollheim; H Zacharaie
Journal:  J Rheumatol       Date:  1999-10       Impact factor: 4.666

8.  Racial differences in scleroderma among women in Michigan.

Authors:  T J Laing; B W Gillespie; M B Toth; M D Mayes; R H Gallavan; C J Burns; J R Johanns; B C Cooper; B J Keroack; M C Wasko; J V Lacey; D Schottenfeld
Journal:  Arthritis Rheum       Date:  1997-04

9.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

10.  Epidemiology of systemic sclerosis (scleroderma).

Authors:  T A Medsger; A T Masi
Journal:  Ann Intern Med       Date:  1971-05       Impact factor: 25.391

  10 in total
  6 in total

1.  Late-age onset systemic sclerosis.

Authors:  Rebecca L Manno; Fredrick M Wigley; Allan C Gelber; Laura K Hummers
Journal:  J Rheumatol       Date:  2011-06-17       Impact factor: 4.666

2.  Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics.

Authors:  Jennifer L Sargent; Zhenghui Li; Antonios O Aliprantis; Matthew Greenblatt; Raphael Lemaire; Ming-Hua Wu; Jun Wei; Jaclyn Taroni; Adam Harris; Kristen B Long; Chelsea Burgwin; Carol M Artlett; Elizabeth P Blankenhorn; Robert Lafyatis; John Varga; Stephen H Clark; Michael L Whitfield
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

3.  Targeting the unfolded protein response, XBP1, and the NLRP3 inflammasome in fibrosis and cancer.

Authors:  Beth Overley-Adamson; Carol M Artlett; Connie Stephens; Sihem Sassi-Gaha; Ransome D Weis; James D Thacker
Journal:  Cancer Biol Ther       Date:  2014-02-04       Impact factor: 4.742

4.  Systemic Sclerosis in Zimbabwe: Autoantibody Biomarkers, Clinical, and Laboratory Correlates.

Authors:  Elopy N Sibanda; Yvonne Dube; Mazvita Chakawa; Takafira Mduluza; Francisca Mutapi
Journal:  Front Immunol       Date:  2021-11-09       Impact factor: 7.561

5.  Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients.

Authors:  Marco A Alba; César Velasco; Carmen Pilar Simeón; Vicent Fonollosa; Luis Trapiella; María Victoria Egurbide; Luis Sáez; María Jesús Castillo; José Luis Callejas; María Teresa Camps; Carles Tolosa; Juan José Ríos; Mayka Freire; José Antonio Vargas; Gerard Espinosa
Journal:  Medicine (Baltimore)       Date:  2014-03       Impact factor: 1.889

6.  Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets.

Authors:  Pia Moinzadeh; Kathrin Kuhr; Elise Siegert; Ulf Mueller-Ladner; Gabriela Riemekasten; Claudia Günther; Ina Kötter; Jörg Henes; Norbert Blank; Gabriele Zeidler; Christiane Pfeiffer; Aaron Juche; Ilona Jandova; Jan Ehrchen; Marc Schmalzing; Laura Susok; Tim Schmeiser; Cord Sunderkoetter; Jörg H W Distler; Margitta Worm; Alexander Kreuter; Thomas Krieg; Nicolas Hunzelmann
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.